Drug giant Roche will buy gene therapy developer Spark Therapeutics for about $4.8 billion in cash, according to Bloomberg.
Roche will pay $114.50 per share, more than twice Spark's closing price on Feb. 22.
The deal will give Roche access to a gene therapy for blindness priced at $850,000 per patient, as well as other projects for hemophilia and neurodegenerative disorders like Huntington's disease.
Roche's deal comes as other big-name drugmakers pivot to gene therapy.
Read the full report here.